You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
|
|---|---|
| Published in |
BMC Cancer, July 2012
|
| DOI | 10.1186/1471-2407-12-305 |
| Pubmed ID | |
| Authors |
David A Palma, Cornelis J A Haasbeek, George B Rodrigues, Max Dahele, Michael Lock, Brian Yaremko, Robert Olson, Mitchell Liu, Jason Panarotto, GwendolynHMJ Griffioen, Stewart Gaede, Ben Slotman, Suresh Senan |
| Abstract |
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control. Survival outcomes for patients with oligometastatic disease treated with SABR appear promising, but conclusions are limited by patient selection, and the lack of adequate controls in most studies. The goal of this multicenter randomized phase II trial is to assess the impact of a comprehensive oligometastatic SABR treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions, compared to patients who receive standard of care treatment alone. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 153 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Spain | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 149 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 20 | 13% |
| Researcher | 20 | 13% |
| Student > Master | 14 | 9% |
| Student > Postgraduate | 13 | 8% |
| Student > Ph. D. Student | 12 | 8% |
| Other | 37 | 24% |
| Unknown | 37 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 76 | 50% |
| Physics and Astronomy | 9 | 6% |
| Nursing and Health Professions | 7 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Agricultural and Biological Sciences | 3 | 2% |
| Other | 10 | 7% |
| Unknown | 45 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2018.
All research outputs
#15,270,147
of 22,787,797 outputs
Outputs from BMC Cancer
#4,083
of 8,290 outputs
Outputs of similar age
#104,120
of 164,407 outputs
Outputs of similar age from BMC Cancer
#44
of 79 outputs
Altmetric has tracked 22,787,797 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,290 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,407 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.